Straits Times Index
3,316.56 -6.06 (-0.18%) Nikkei
38,646.11 -457.11 (-1.17%) Hang Seng
18,608.94 -259.77 (-1.38%) FTSE 100
8,317.59 -21.64 (-0.26%) Bitcoin USD
68,620.67 +970.74 (+1.43%) CMC Crypto 200
1,436.56 -31.54 (-2.15%)
STOK Aug 2024 10.000 call
| Previous close | 3.0300 |
| Open | 3.0300 |
| Bid | 4.5000 |
| Ask | 6.4000 |
| Strike | 10.00 |
| Expiry date | 2024-08-16 |
| Day's range | 3.0300 - 3.0300 |
| Contract range | N/A |
| Volume | |
| Open interest | 12 |
GuruFocus.comInsider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares
On May 20, 2024, Edward M. Kaye, MD, Chief Executive Officer of Stoke Therapeutics Inc (NASDAQ:STOK), executed a significant stock transaction, selling 42,350 shares of the company.
Business WireStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass., May 17, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on May 15, 2024, the company granted stock options of common stock to Thomas Leggett, the Company’s newly-appointed Chief Financial Officer, and four other new employees as a material inducement to their employment in accordance with Nasdaq Listing
GuruFocus.comStoke Therapeutics Inc (STOK) Reports Q1 2024 Financial Results: A Closer Look at Challenges ...
Despite Narrow Miss on EPS, Stoke Therapeutics Advances in Clinical Developments
